DR. THOMAS DWIGHT BIRD, MD
Medical Practice in Seattle, WA

6468791, Oct 22, 2002

Aug 16, 1999

09/375318

Rudolph E. Tanzi - Canton MA
Gerard D. Schellenberg - Seattle WA
Wilma Wasco - Cambridge MA
Thomas D. Bird - Seattle WA
David J. Galas - Mercer Island WA

The General Hospital Corp. - Boston MA
University of Washington - Seattle WA

C12N 1500

435325, 435 691, 4353201, 536 231, 536 2431, 536 235

The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimers Disease.

5449604, Sep 12, 1995

Oct 21, 1992

7/964151

Gerard D. Schellenberg - Seattle WA
Thomas D. Bird - Seattle WA
Ellen M. Wijsman - Seattle WA

University of Washington - Seattle WA

C12Q 168, C12P 1934

435 6

Method for isolating a DNA segment indicative of an Alzheimer's disease trait in a family population, wherein said family population consists essentially of a plurality of blood relatives of an individual having a chromosome 14 Alzheimer's disease trait, by: preparing a test sample of immobilized separated genomic DNA fragments from a plurality of the blood relatives, contacting each of the test samples with a test oligonucleotide under conditions permitting hybridization of complementary single stranded DNA molecules, wherein the test oligonucleotide is complementary with at least a portion of a genetic marker located between band q11. 2 and band q32. 1 in chromosome 14, identifying a plurality of hybridized molecules so formed as alleles of the genetic marker in the family population, identifying one of the genetic marker alleles as indicative of the Alzheimer's disease trait in the family population by either determining by pedigree analysis a segregation value for each of the genetic markers alleles and the Alzheimer's disease trait, and selecting an indicative genetic marker allele that co-segregates with the Alzheimer's disease trait in the family population, or measuring genetic linkage between each of the genetic marker alleles and the Alzheimer's disease trait, and selecting a genetic marker allele as indicative of the Alzheimer's disease trait in the family population if the selected genetic marker allele has a maximal LOD score of at least 3 at a recombination fraction of about 0. 0 to about 0. 1 for genetic linkage with the Alzheimer's disease trait in the family population, and isolating a chromosome 14 DNA segment containing the indicative genetic marker allele.

7655401, Feb 2, 2010

Sep 25, 2003

10/671007

Wendy H. Raskind - Seattle WA, US
Dong-Hui Chen - Seattle WA, US
Thomas D. Bird - Lake Forest Park WA, US
Zoran Brkanac - Seattle WA, US

University of Washington - Seattle WA

C12Q 1/68, C12Q 1/44, C12P 19/34, C07H 21/00

435 6, 435 19, 435 912, 536 2532

In one aspect, the invention provides methods of identifying genetic mutations that are associated with ataxic neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a protein kinase C gamma gene from a mammalian subject exhibiting ataxia and a nucleic acid sequence of a protein kinase C gamma gene from a subject which is not exhibiting ataxia, wherein the difference is a genetic mutation associated with ataxic neurological disease. In another aspect, isolated nucleic acid molecules encoding protein kinase C gamma missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop an ataxic neurological disease is provided. In another aspect, the invention provides kits for determining susceptibility or presence of ataxic neurological disease in a mammalian subject.

7449291, Nov 11, 2008

Jan 13, 2004

10/756194

Phillip F. Chance - Seattle WA, US
Valerie A. Street - Seattle WA, US
Jeff D. Goldy - Seattle WA, US
Thomas D. Bird - Lake Forest Park WA, US

University of Washington - Seattle WA

C12Q 1/68, C12Q 1/00, G01N 33/567, G01N 33/53, C07H 21/02, C07H 21/04

435 6, 435 4, 436504, 436501, 536 231, 536 243

In one aspect, the invention provides methods of identifying genetic mutations that are associated with peripheral neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a small integral protein of the lysosome/late endosome (“SIMPLE”) gene from a mammalian subject exhibiting peripheral neuropathy and a nucleic acid sequence of a SIMPLE gene from a subject which is not exhibiting peripheral neuropathy, wherein the difference is a genetic mutation associated with peripheral neurological disease. In another aspect, isolated nucleic acid molecules encoding SIMPLE missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop Charcot-Marie-Tooth type 1C neuropathy is provided. In another aspect, the invention provides kits for determining susceptibility or presence of Charcot-Marie-Tooth type 1C neuropathy in a mammalian subject.

2010012, May 27, 2010

Dec 4, 2009

12/631722

Wendy H. Raskind - Seattle WA, US
Dong-Hui Chen - Seattle WA, US
Thomas D. Bird - Lake Forest Park WA, US
Zoran Brkanac - Seattle WA, US

WASHINGTON, UNIVERSITY OF - Seattle WA

C12Q 1/68, C07H 21/04

435 6, 536 232

In one aspect, the invention provides methods of identifying genetic mutations that are associated with ataxic neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a protein kinase C gamma gene from a mammalian subject exhibiting ataxia and a nucleic acid sequence of a protein kinase C gamma gene from a subject which is not exhibiting ataxia, wherein the difference is a genetic mutation associated with ataxic neurological disease. In another aspect, isolated nucleic acid molecules encoding protein kinase C gamma missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop an ataxic neurological disease is provided. In another aspect, the invention provides kits for determining susceptibility or presence of ataxic neurological disease in a mammalian subject.

2003018, Sep 25, 2003

Jun 24, 2002

10/180781

Rudolph Tanzi - Hull MA, US
Gerard Schellenberg - Seattle WA, US
Wilma Wasco - Arlington MA, US
Ephrat Levy-Lahad - Jerusalem, IL
Thomas Bird - Seattle WA, US
David Galas - Claremont CA, US

University of Washington - Seattle WA

C12P021/02, C07K014/435, C07H021/04, C12N005/08

435/069100, 435/320100, 435/368000, 435/325000, 530/350000, 536/023500

The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.